Portola Pharma (PTLA) Reports In-Line Q1 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 8, 2019 8:01 AM EDTFirst Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 MillionÂ
European Commission Approval of Ondexxya®; Staged Commercial Launch Planned in Second Half of 2019Â
Conference Call Today at 5:30 a.m. PT / 8:30 a.m. ET
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2019 and provided a corporate update.
Our first quarter results continue to... More
